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A B S T R A C T
Mycosis fungoides (MF) and Se´zary syndrome (SS), the major forms of cutaneous T-cell
lymphoma, have unique characteristics that distinguish them from other types of non-Hodgkin’s
lymphomas. Clinical trials in MF/SS have suffered from a lack of standardization in evaluation,
staging, assessment, end points, and response criteria. Recently defined criteria for the diagnosis
of early MF, guidelines for initial evaluation, and revised staging and classification criteria for MF
and SS now offer the potential for uniform staging of patients enrolled in clinical trials for MF/SS.
This article presents consensus recommendations for the general conduct of clinical trials of
patients with MF/SS as well as methods for standardized assessment of potential disease
manifestations in skin, lymph nodes, blood, and visceral organs, and definition of end points and
response criteria. These guidelines should facilitate collaboration among investigators and collation
of data from sponsor-generated or investigator-initiated clinical trials involving patients with MF
or SS.
J Clin Oncol 29:2598-2607. © 2011 by American Society of Clinical Oncology
INTRODUCTION
Mycosis fungoides (MF) and Se´zary syndrome (SS)
are the most common variants of cutaneous T-cell
lymphoma (CTCL).1-3 The prognosis of MF and SS
depends on the type and extent of skin lesions and
extracutaneous disease,4 which were first captured
in the TNM classification published for CTCL in
1979.5 Suggested modifications published in 2007
for MF/SS1 (Tables 1 and 2) revised the nodal clini-
copathologic classification, added blood involve-
ment to the staging of MF/SS, and removed the
ambiguity surrounding variables critical to a stan-
dardized staging and classification system.
The final barrier to collaborative clinical trials
of MF and SS is the lack of standardized end points
and response criteria. Standardization would facili-
tate: (1) the approval of effective new treatments for
MF/SS by expediting protocol development and re-
view; (2) consolidation or comparison of data on a
given therapy for MF/SS collected at multiple sites
and/or at different time points; and (3) comparison
of efficacy results of various therapeutic agents for
MF/SS evaluated in different clinical trials.
From eight workshops held in 2004 to 2009, the
International Society for Cutaneous Lymphomas
(ISCL), the United States Cutaneous Lymphoma
Consortium (USCLC), and the Cutaneous Lym-
phoma Task Force of the European Organisation for
Research and Treatment of Cancer (EORTC) devel-
oped the following consensus guidelines to resolve
this deficiency. These guidelines include: recom-
mendations for standardizing general protocol de-
sign; a scoring system for assessing tumor burden in
skin, lymph nodes, blood, and viscera; definition of
response in skin, nodes, blood, and viscera; a com-
posite global response score; and a definition of
end points.
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STUDY DESIGN
For all clinical trials in MF/SS, the following is recommended6:
1. The definition of patch, plaque, and tumor should be as
outlined in Table 1.
2. For study eligibility, the histopathologic diagnosis should be
confirmed in a skin biopsy representative of current disease by a
pathologist with expertise in cutaneous lymphoma. For SS (defined as
meeting T4 plus B2 criteria
1), where the biopsy of erythrodermic skin
may only reveal suggestive but not diagnostic histopathologic features,
the diagnosis may be based on either a node biopsy or fulfillment of B2
criteria1 including a clone in the blood that matches that of the skin.
For early patch stage MF where the histological diagnosis by light
microscopic examination is not confirmed, diagnostic criteria that
have been recommended by the ISCL should be used.6 A biopsy
performed at baseline (pre-entry) is preferred as it reflects the current
status of disease, may be necessary to assess histologic findings in-
cluded in the inclusion/exclusion criteria, may give information on
Table 1. Modified ISCL/EORTC Revisions to the TNMB Classification
of MF/SS1
TNMB Stages Description of TNMB
Skin
T1 Limited patches, papules, and/or plaques covering
 10% of the skin surface; may further stratify into
T1a (patch only) v T1b (plaque  patch)
T2 Patches, papules, or plaques covering  10% of the
skin surface; may further stratify into T2a (patch only) v
T2b (plaque  patch)
T3 One or more tumors ( 1 cm diameter)
T4 Confluence of erythema covering  80% body surface
area
Node†
N0 No clinically abnormal lymph nodes; biopsy not required
N1 Clinically abnormal lymph nodes; histopathology Dutch
grade 1 or NCI LN0-2
N1a Clone negative
N1b Clone positive
N2 Clinically abnormal lymph nodes; histopathology Dutch
Grade 2 or NCI LN3
N2a Clone negative
N2b Clone positive
N3 Clinically abnormal lymph nodes; histopathology Dutch
grade 3-4 or NCI LN4; clone positive or negative
Nx Clinically abnormal lymph nodes without histologic
confirmation or inability to fully characterize the
histologic subcategories
Visceral
M0 No visceral organ involvement
M1 Visceral involvement (must have pathology confirmation
and organ involved should be specified)
Blood
B0 Absence of significant blood involvement:  5% of pe-
ripheral blood lymphocytes are atypical (Sézary) cells
B0a Clone negative
B0b Clone positive
B1 Low blood tumor burden:  5% of peripheral blood
lymphocytes are atypical (Sézary) cells but does not
meet the criteria of B2
B1a Clone negative
B1b Clone positive
B2 High blood tumor burden:  1,000/L Sézary cells with
positive clone‡; one of the following can be
substituted for Sézary cells: CD4/CD8  10,
CD4CD7- cells  40% or CD4CD26- cells  30%
Abbreviations: ISCL, International Society for Cutaneous Lymphomas;
EORTC, European Organisation for Research and Treatment of Cancer; MF,
mycosis fungoides; SS, Sézary syndrome; NCI, National Cancer Institute.
Patch  any size lesion without induration or significant elevation above the
surrounding uninvolved skin: pokiloderma may be present. Plaque  any size
lesion that is elevated or indurated: crusting or poikiloderma may be present.
Tumor any solid or nodular lesion 1 cm in diameter with evidence of deep
infiltration in the skin and/or vertical growth.
†Lymph node classification has been modified from 2007 ISCL/EORTC
consensus revisions1 to include central nodes. Lymph nodes are qualified as
abnormal if  1.5 cm in diameter.
‡The clone in the blood should match that of the skin. The relevance of an
isolated clone in the blood or a clone in the blood that does not match the
clone in the skin remains to be determined.
Table 2. Modified ISCL/EORTC Revisions to the Staging of MF/SS1
Stage T N M B
IA 1 0 0 0, 1
IB 2 0 0 0, 1
IIA 1-2 1, 2, X 0 0, 1
IIB 3 0-2, X 0 0, 1
IIIA 4 0-2, X 0 0
IIIB 4 0-2, X 0 1
IVA1 1-4 0-2, X 0 2
IVA2 1-4 3 0 0-2
IVB 1-4 0-3, X 1 0-2
Abbreviations: ISCL, International Society for Cutaneous Lymphomas;
EORTC, European Organisation for Research and Treatment of Cancer; MF,
mycosis fungoides; SS, Sézary syndrome; X, clinically abnormal lymph nodes
without histologic confirmation or inability to fully characterize histologic
subcategories.
Table 3. Modified Severity Weighted Assessment Tool
Body Region
% BSA in Body
Region
Assessment of Involvement
in Patient’s Skin
Patch Plaque† Tumor‡
Head 7
Neck 2
Anterior trunk 13
Arms 8
Forearms 6
Hands 5
Posterior trunk 13
Buttocks 5
Thighs 19
Legs 14
Feet 7
Groin 1
Subtotal of lesion BSA
Weighting factor 1 2 4
Subtotal lesion BSA 
weighting factor
NOTE. mSWAT score equals summation of each column line.
Abbreviations: BSA, body surface area; mSWAT, modified Severity
Weighted Assessment Tool.
Any size lesion without induration or significant elevation above the sur-
rounding uninvolved skin; poikiloderma may be present.
†Any size lesion that is elevated or indurated; crusting, ulceration, or
poikiloderma may be present.
‡Any solid or nodular lesion  1 cm in diameter with evidence of deep
infiltration in the skin and/or vertical growth.
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prognosis (eg, large cell transformation or folliculotropism) that is
unanticipated and important for stratification of cohorts in a random-
ized controlled trial (RCT), and provides adequate tissue for any
additional correlative studies. However, a prior tissue specimen can be
used for diagnostic purposes provided that the type of lesion biopsied
is representative of current skin lesions, the study pathologist finds it
meets the current criteria for MF/SS, it provides sufficient information
for all inclusion/exclusion and stratification purposes, and the patient
has not experienced progressive disease since the biopsy was per-
formed. All skin biopsies should be done after a time period off any
therapy that may affect the histologic interpretation or diagnostic
criteria important to the clinical trial—this primarily affects patch
lesions and 2 to 4 weeks off therapy generally suffices.
3. If subjects are enrolled onto an RCT with clinical or histologic
variants of MF (eg, hypopigmented MF, granulomatous slack skin,
folliculotropic MF) or with other than skin histopathologic criteria for
study entry, consideration should be given to stratification of treat-
ment groups and separate reporting of study results for these variants.
4. There should be a wash-out time period from any treatment
likely to affect the course of MF/SS and therefore the inclusion/exclu-
sion criteria or the subsequent assessment of the efficacy and safety of the
studytreatment.Althougha4-weekwash-outperiodisrecommendedfor
most participants in order to minimize any latent clinical benefit or resid-
ual toxicity from the prior treatment, this time period is best determined
based on the biologic effects of the therapy and whether the patient is
experiencing progressive disease despite ongoing treatment.
5. An exception to concurrent therapy with proven efficacy in
MF/SS is topical or systemic steroids in those patients with erythroderma
who have been on corticosteroids for prolonged periods of time and
where discontinuation may lead to rebound flare in disease, adrenal
insufficiency, and/or unnecessary suffering. In these cases, the contin-
ued use during the trial of either low-dose systemic steroid (equivalent
to10 mg per day of prednisone) or low potency topical steroids may
be considered if the frequency and dosage of either has been constant
for a period of time before the study and will remain constant until
improvement occurs at which time dosage may be decreased. How-
ever, no complete response (CR) can be ascribed to a study drug while
a patient remains on concomitant therapy with known efficacy in
MF/SS (including topical or systemic steroids), but rather the maxi-
mum response to study drug would be a partial response (PR).
Those patients in whom a PR was achieved only while on combi-
nation therapy with any such agent should be so noted in the final
study report.
6. RCTs that utilize a control group of similar patient character-
istics and prior treatments and who are being treated with a therapeu-
tic agent previously shown to have efficacy in this disease remain
the ideal and a goal that cooperative studies in MF/SS may help to
meet. The utilization of historical controls is suboptimal as there is
the potential for underestimation of the response rate of controls,7
and specifically in MF/SS, a difference in the diagnostic or entrance
criteria and/or prior treatments utilized in the current and com-
parative groups.
7. For the purposes of determining enrollment eligibility and/or
stratification of treatment groups, the maximum TNMB staging
reached as well as the current disease activity (global score) at entry
should be considered. This will help ensure that information impor-
tant to outcome/prognosis is available at study onset and considered
in any trial results.
8. It is important for purposes of TNMB assignment that before
a patient enters a clinical trial, any abnormal lymph node be charac-
terized histologically. An excisional biopsy of a representative en-
larged or otherwise abnormal peripheral node is recommended to
determine the architectural changes that characterize the N1-3 his-
tologic categories.1 However, this type of biopsy carries the risks of
infection, bleeding, and lymphedema, and repetitive excisions in
the same nodal region are to be avoided. Therefore, the most recent
excisional biopsy of a representative abnormal lymph node may be
used for baseline nodal classification as long as there has been
persistent and stable lymph node enlargement and, in the case of
N1-2 classification on prior biopsy, stable lymph node size since the
time of that biopsy even if there have been multiple treatments
since the last node biopsy.
9. The frequency of direct patient assessment in a given protocol
should take into account the specifics of the type and schedule of
treatment and the patient’s TNMB status. Where the duration of a
given treatment effect is to be determined or where the response
duration is being tracked as an end point in the trial, follow-up at least
monthly is recommended to avoid overestimation of the duration of
the effect/response. The frequency of the assessment of lymph node,
viscera, and/or blood involvement by other than physical examination
should be determined by the patient’s TNMB status, the response in
skin, and the need/desire to assess global response.
10. The pretreatment evaluation and scoring of response pa-
rameters should be done at baseline (day 1 of treatment), and not at
screening. These scores will constitute the comparison values for all
response measurements during the study.
11. All responses should be documented to be at least 4 weeks in
duration: an objective response (CR or PR) for a lesser period of time
is of questionable value and runs the risk of being unrelated to the
study drug (eg, improvement while on a course of antibiotics). In cases
where the definition of progressive disease (PD) or relapse is met but
the clinical impression is questionable, documentation for a period of
at least 4 weeks is also recommended to avoid a patient being removed
prematurely from the study.
12. To be consistent with that of other NHLs, the definition of
PD during a clinical trial of patients with MF/SS would include both
nonresponders who meet the definition of PD and responders who
meet the definition of loss of response. It is acknowledged that a loss of
response in responders (PR plus CR) and/or a relapse in those patients
with a CR may have different prognostic implications than PD in
nonresponders and that the precise definition of PD used in any given
trial should be reported.
13. The duration of a given study should be long enough to
ensure that a significant response is able to occur and that it is sus-
tained. If time to an event is also a goal (such as time to PD), then
routine evaluation off therapy may be indicated.
14. Primary statistical analysis in an efficacy trial should be
based on the intention-to-treat population.
SKIN ASSESSMENT, SCORING, AND DEFINITION OF RESPONSE
Skin Assessment and Scoring
Total body skin scoring. The most widely used method for skin
scoring is the Severity Weighted Assessment Tool (SWAT)8,9 or its
Olsen et al
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modification, the mSWAT.10 This technique involves the direct as-
sessment of the body-surface area (BSA) of each type of MF/SS lesion
(palm plus fingers of the patient approximately 1% BSA) in each of
12 areas of the body, multiplying the sum of the BSA of each lesion
type by a weighting factor (patch1, plaque2, and tumor3 or 4)
and generating a sum of the subtotals of each lesion subtype (Table 3;
Appendix Fig A1, online only).
There has been much discussion about the appropriate weighting
factor for tumors given their prognostic importance. The thickness of
the dermal infiltrate of tumors in MF11 is far greater than 4 times that
of patches (the current weighting factor for tumors in the mSWAT
score) as is the proportion of neoplastic cells. As currently constructed
in the mSWAT, any change in tumor size or number will be under-
represented in the total mSWAT compared to changes in patch and
plaque lesions. However, the variability of investigators in assigning a
lesion to plaque versus tumor is quite high (unpublished data, E.
Vonderheid, 2003; unpublished data, E. Olsen, 2006), which compli-
cates the simple remedy of increasing the weighting factor of tumor
versus patch/plaque and underscores the importance of a single asses-
sor during a clinical trial.
It would be ideal if the same scoring system could be used for
both MF and SS. Methods that have been employed to track response
in SS and erythrodermic MF in clinical trials and their relative benefits
and drawbacks are presented in Table 4.9,10,12 Although not specifi-
cally previously noted, the mSWAT can be utilized to track erythro-
derma by the summation of BSA involved with patch disease (macular
erythema) and plaque disease (erythema with induration/edema)
while maintaining the ability to simultaneously track any tumors that
may be present. Patients assigned the diagnosis of erythrodermic MF
or SS should fulfill the ISCL criteria of erythroderma (T4 skin classifi-
cation; ie, BSA 80% erythematous patch/plaque disease).13
Standardized photographs of the skin are recommended to doc-
ument the appearance of skin lesions at baseline and at times of re-
sponse/progression.
Local/or index/target lesion skin scoring. There are circumstances
where local index lesion skin scoring is particularly useful in determin-
ing the effectiveness of a treatment for MF, such as in studies targeting
some but not all lesions or where it is desirable to monitor the effect of
treatment to only one type of lesion. One such method of index lesion
scoring for patch/plaque disease is the Composite Assessment of Index
Lesion Severity (CA or CAILS; Table 5).14 Another simpler method of
local skin scoring is to determine the sum of the area of each target
lesion multiplied by the weight assigned to the lesion type (ie, patch
1, plaque 2, tumor 4 as with mSWAT); this eliminates the CAILS
pigmentation severity score and the potential over- or underestima-
tion in the BSA that may be seen with the CAILS. Tumors may be
tracked by either utilizing the tumor column of the mSWAT score or
by the summation of the area  height for each tumor (index or
all lesions).
There are, however, inherent problems with any index scoring
system being used as the sole skin score for MF/SS: these methods
make it possible to record a CR in the situations where all target lesions
clear even if nonindex/nontarget lesions persist or even progress or
where new lesions outside the index/target lesions appear and are not
responsive to therapy. Given that a global score should include an
assessment of the entire skin surface, local index/target lesion scoring
should not be used in a global scoring system for MF/SS.
Definition of Response in Skin
It is recommended that the mSWAT in a given clinical trial be
performed at the bedside by the same investigator at all time points to
eliminate inter-observer variability for a given patient. If the same
investigator cannot perform all the assessments, then all personnel
grading the same patient must have completed prior training, ideally
before study initiation.
Table 4. Methods of Assessment of Erythroderma Used in Various Clinical Trials of MF/SS
Reference Method Comments
Edelson et al12 Percent skin involvement in various body regions multiplied
by a 0-4 point severity scale that includes degrees of
erythema, edema, exfoliation, fissuring, and induration
Severity factors not considered individually
Olsen et al9 Specific erythroderma scale that includes both extent and
severity of involvement
A minor change in severity can profoundly affect the
overall score
Olsen et al10 Visual analog scale of 0-10 Global physician score that combines extent with severity
but does not define specifics of either
This article Patch plus plaque sections of mSWAT score; sum of BSA
involved with patch disease  weighting factor of 1 plus
plaque disease  weighting factor of 2
No additional work if already performing mSWAT; does
not track fissures or scale/exfoliation separately
Abbreviations: MF, mycosis fungoides; SS, Sézary syndrome.
Table 5. Composite Assessment of Index Lesion Severity
Clinical Sign and Degree or Size
(scale of 0-8)
Index Lesion
1 2 3 4 5
Erythema
Scaling
Plaque elevation
Hypo- or hyperpigmentation
Lesion size
Subtotal
Total (sum of subtotals)
NOTE. Cannot be used as skin assessment in global response score.
Suggestions for improvement include using actual size of lesion versus
categorical score for size and eliminating pigmentation as a clinical parameter.
Lesion size (cm2): 0: no measurable area; 1:  0 to  4; 2:  4 to  10; 3:
 10 to  16; 4:  16 to  25; 5:  25 to  35; 6:  35 to  45; 7:  45 to
 55; 8: 55 to 70; 9: 70 to 90; 10: 90 to 110; 11: 110 to 130;
12:  130 to  155; 13:  155 to  180; 14:  180 to  210; 15:  210
to  240; 16:  240 to  270; 17:  270 to  300; 18:  300.
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The definition of response in skin of patients with MF/SS is as
presented in Table 6. Absence of T-cell receptor (TCR) gene rear-
rangement clonality in the skin as additional evidence of clearing15 has
not been validated for use in clinical trials.
LYMPH NODE ASSESSMENT, SCORING, AND DEFINITION
OF RESPONSE
Physical examination alone is an unreliable method for determining
the size of peripheral lymph nodes16 and is inadequate to assess in-
volvement of internal organs. Therefore, when it is important to fully
characterize the TNMB status of participants and to be able to make an
assessment of global response during a clinical trial, computed tomog-
raphy (CT) imaging is recommended to be used with the caveat that
considerable inter-observer variability exists even for CT scans.17
However, a concern that is now gaining attention is the radiation
exposure associated with different imaging studies. For example, a
single abdominal CT scan versus a PA and lateral chest x-ray exposes
the patient to approximately 0.01 Gy compared with 0.000015 mGy
radiation respectively.18 An [18F] fluorodeoxyglucose (FDG) positron
emission tomography (PET) scan gives additional information on the
likelihood of involvement by lymphoma but may have false positive
results with infection or inflammation19 and essentially doubles the
radiation exposure and cost of a CT scan. Given the likelihood that
many patients with MF/SS will undergo multiple CT scans during
their lives, the number of CT or FDG-PET/CT scans during individual
clinical trials should be minimized.
In clinical trials of patients with MF/SS in whom global response
is to be determined, it is recommended that CT scans be performed at
screening/baseline in all patients. In those patients with clinically early
disease (maximum/current T1-2N0M0B0-1), repeat scans are not rec-
ommended except in cases of an objective response (OR) in the skin
where this is necessary for determination of global response or if there
is a suggestion of new nodal or visceral involvement. In those patients
with more advanced disease at baseline (maximum/current TNMB
greater than T1-2N0M0B0-1), repeat imaging studies should be per-
formed at the time of PR and CR in the skin; any time there is a
question of new or PD in the lymph nodes or viscera; and at end of
study. Although FDG-PET scans may be useful to corroborate a CR in
the nodes or viscera in patients with other forms of NHL,19 the limited
data on FDG-PET scans in MF/SS, the additional radiation, the cost of
sequential FDG-PET scans, and the difficulty distinguishing tissue
inflammation from that related to lymphoma in MF/SS do not war-
rant its routine use as an assessment tool in clinical trials of MF/SS at
this time.
Magnetic resonance imaging is an alternative to CT that gives
accurate information on the size of lymph nodes and viscera without
radiation exposure, but it is costly and its use is limited in patients with
compromised renal function. While ultrasound would seem a desir-
able method to evaluate peripheral lymph nodes, given that bi-
dimensional measurements are possible without ionizing radiation,
unfortunately there is a lack of consistent repetitive measurements
based on the variability in imaging planes and the entire examination
cannot be reproduced for independent review at a later time point.
A repeat peripheral lymph node biopsy during a clinical trial is
only recommended in situations where the histology would affect the
global response score. Examples include when a patient without ab-
normal nodes at baseline develops new lymphadenopathy of unclear
etiology or when a patient with known lymphomatous involvement
(N3) of a peripheral lymph node that was 1.5 cm in the long axis or
 1 cm in the short axis has a persistent lymph node larger than 1 cm
in diameter in the short axis. Although a repeat excisional biopsy is
preferred, to avoid possible morbidity, consideration should be made
as to whether either a fine needle aspirate or core biopsy with support-
ive ancillary studies such as flow cytometry and/or molecular TCR
gene analysis in addition to cytology may suffice for response assess-
ment. Any equivocal or absent pathologic assessment of an abnormal
lymph node should be considered Nx and not considered for a desig-
nation of CR. All other assessments of peripheral node response dur-
ing a clinical trial would be by the sum of the product of the longest
bidimensional diameters (SPD) of the lymph nodes seen on CT (ie, by
size alone).19
Central lymph nodes were not previously addressed in MF/SS
staging because they are generally only seen in late disease when other
extracutaneous sites are also involved and are not easily amenable to
biopsy confirmation. However, modifications to the 2007 revisions to
the staging and classification of MF/SS have been made (Table 1). If
there is evidence of enlarged central nodes (defined as  1.5 cm
diameter in the long axis or 1.0 cm diameter in the short axis), and
confirmation of involvement with MF/SS by biopsy (ie, excisional,
fine needle aspirate, or core biopsy), then all central nodes should be
tracked thereafter in the same way as peripheral nodes (product of the
longest bidimensional measurements of all enlarged nodes).
The definition of response in lymph nodes is given in Table 7.
VISCERAL DISEASE ASSESSMENT, SCORING, AND DEFINITION
OF RESPONSE
Biopsy confirmation at baseline is recommended for all forms of
visceral disease except for liver and spleen involvement, which may
Table 6. Response in Skin
Response Definition
Complete
response 100% clearance of skin lesions
Partial response 50%-99% clearance of skin disease from baseline
without new tumors (T3) in patients with T1, T2 or T4
only skin disease
Stable disease  25% increase to  50% clearance in skin disease
from baseline without new tumors (T3) in patients
with T1, T2, or T4 only skin disease
Progressive
disease†
 25% increase in skin disease from baseline or
New tumors (T3) in patients with T1, T2 or T4 only skin
disease or
Loss of response: in those with complete or partial
response, increase of skin score of greater than the
sum of nadir plus 50% baseline score
Relapse Any disease recurrence in those with complete response
NOTE. Based on modified Severity Weighted Assessment Tool score.
A biopsy of normal appearing skin is unnecessary to assign a complete
response. However, a skin biopsy should be performed of a representative
area of the skin if there is any question of residual disease (persistent
erythema or pigmentary change) where otherwise a complete response
would exist. If histologic features are suspicious or suggestive of mycosis
fungoides/Sézary syndrome (see histologic criteria for early mycosis fungoi-
des7), the response should be considered a partial response only.
†Whichever criterion occurs first.
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be diagnosed by imaging studies.1 It is unclear whether bone mar-
row involvement in MF/SS should be considered as visceral disease
or if it represents an additional prognostic factor in patients with
SS. However, many investigators consider bone marrow involve-
ment in MF/SS to be an extension of blood involvement (B2) and
not visceral disease, and hence, bone marrow aspirate/trephine
biopsies are not considered obligatory for either evaluation or
response assessment.
There may be limitations in corroborating a CR in viscera by CT
alone20,21 and in those cases, a confirmatory biopsy may be necessary
or lacking this, no CR assessment can be made.
Definition of response in viscera is given in Table 8.
BLOOD ASSESSMENT, SCORING, AND DEFINITION
OF RESPONSE
While a variety of measures for defining blood involvement for staging
has utility in clinical practice, tracking blood involvement in clinical
trials requires use among all participating centers of a single method
that both defines and quantifies blood neoplastic cells including insig-
nificant or absent blood involvement. Currently, this will require
consideration of additional definitions of B0 and B2 for the purpose of
clinical trials that are outside those used for staging purposes alone.
The prognostic implications, benefits, and drawbacks of the various
current methods of quantification of neoplastic blood involvement in
MF/SS are discussed below.
Se´zary cell quantification is one potential means of monitor-
ing blood tumor burden in a clinical trials setting. B0 has long been
defined as 5% Se´zary cells1,5 and there is precedence for defining
B2 as more than 20% Se´zary cells since the latter both correlates
with prognosis (although not independent of skin stage)22 and is
relatively specific for MF/SS (all 71 control subjects in one study
having had 20% Se´zary cells23). Since B2 is currently defined as
more than 1,000 Se´zary cells/L,1 one could also use an absolute
number versus percentage of Se´zary cells to define B0. Vonderheid
et al24 reported that similar survival results were seen with B0
defined as the absence of a clone and either fewer than 20% Se´zary
cells or fewer than 250 Se´zary cells/L. Although Se´zary cell counts
are subject to considerable inter-observer variability, this hurdle
could be surmounted in a clinical trial by having blood smears
prepared in a standardized fashion at the study sites and sent for
interpretation to an experienced pathologist at a central site. How-
ever, the cerebriform nuclear morphology that characterizes
Se´zary cells is not entirely specific for neoplastic T cells13 and the
number of neoplastic cells determined by Se´zary cell count is often
underestimated compared to flow cytometry.25
Conversely, flow cytometry of T-cell subsets in the blood pro-
vides a more objective, quantifiable, and reproducible means of iden-
tifying and tracking blood involvement in patients with MF/SS. The
CD4CD7- and CD4CD26- subsets are most commonly used to
designate the neoplastic population in MF/SS,25-28 and the percent-
age of each subset currently may be used to define B2 blood in-
volvement.1 However, the loss of these markers on normal T
lymphocytes can occur with aging (CD7)29,30 or with antigenic
stimulation (CD7 and CD26).27,28,31,32 In addition, clonal neoplas-
tic T cells may be present in different populations of CD4 cells33
and/or the population of CD4 cells with loss of expression of CD7
or CD26 may not be the dominant decrease in clone.27,34 This
makes these markers, particularly CD7,35 less applicable for general
use in clinical studies. Also, because a small proportion of normal T
cells express the CD4CD7- or CD4CD26- phenotype, a decrease
in these subsets in the blood may or may not indicate clearance of
neoplastic cells.
Barring these limitations in specificity, utilization of the absolute
number of abnormal lymphocytes by flow cytometric analysis in clin-
ical trials to define B2 would be in line with the current use of absolute
Table 7. Response in Lymph Nodes*
Response Definition
CR All lymph nodes are now  1.5 cm in greatest transverse
(long axis) diameter by method used to assess lymph
nodes at baseline or biopsy negative for lymphoma; in
addition, lymph nodes that were N3 classification and
 1.5 cm in their long axis and  1 cm in their short
axis at baseline, must now be  1 cm in their short
axis or biopsy negative for lymphoma
PR Cumulative reduction  50% of the SPD of each
abnormal lymph node at baseline and no new lymph
node  1.5 cm in the diameter of the long axis or 
1.0 cm in the diameter of the short axis if the long axis
is 1-1.5 cm diameter
SD Fails to attain the criteria for CR, PR, and PD
PD†  50% increase in SPD from baseline of lymph nodes or
Any new node  1.5 cm in the long axis or  1 cm in
the short axis if 1-1.5 cm in the long axis that is proven
to be N3 histologically or
Loss of response:  50% increase from nadir in SPD of
lymph nodes in those with PR
Relapse Any new lymph node  1.5 cm in the long axis in those
with CR proven to be N3 histologically
Abbreviations: CR, complete response; PR, partial response; SPD, sum of
the maximum linear dimension (major axis)  longest perpendicular dimen-
sion (minor axis); SD, stable disease; PD, progressive disease.
*Peripheral and central lymph nodes.
†Whichever criterion occurs first.
Table 8. Response in Viscera
Response Definition
CR Liver or spleen or any organ considered involved
at baseline should not be enlarged on physical
exam and should be considered normal by
imaging; no nodules should be present on
imaging of liver or spleen; any post treatment
mass must be determined by biopsy to be
negative for lymphoma
PR  50% regression in any splenic or liver nodules,
or in measureable disease (SPD) in any organs
abnormal at baseline; no increase in size of liver
or spleen and no new sites of involvement
SD Fails to attain the criteria for CR, PR, or PD
PD  50% increase in size (SPD) of any organs
involved at baseline or
New organ involvement or
Loss of response:  50% increase from nadir in
the size (SPD) of any previous organ
involvement in those with PR
Relapse New organ involvement in those with CR
Abbreviations: CR, complete response; PR, partial response; SPD, sum of the
maximum linear dimension (major axis)  longest perpendicular dimension
(minor axis); SD, stable disease; PD, progressive disease.
Whichever criterion occurs first.
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number versus percentage of Se´zary cells to define B2 and would be
congruent with the tracking of the absolute number of neoplastic cells
in the blood in T-cell leukemias.36 CD26 is lost on CD4 cells in more
than 90% of patients with SS and its loss correlates with morpho-
logically identifiable tumor cells in the blood (96% sensitivity, 98%
specificity).27 Moreover, absolute counts of CD4CD26- cells have
prognostic significance.24
Based on the above, at the current time, the absolute number of
CD4CD26- cells determined by flow cytometry is the most reason-
able, quantifiable measure of potential blood involvement in MF/SS
for clinical trials. In CD26 patients, CD4CD7- T cells would be an
alternate population to monitor. Data suggest that a normal value for
CD4CD26- or CD4CD7- cells by flow cytometry is lower than
15%.27,29,30,32,37 Based on an upper limit of normal value of 1,600/L
for CD4 cells in the blood, an absolute count of lower than 250/L
CD4/CD26- or CD4CD7- cells would appear to be a normal value
for these CD4 subsets and could also be used to define the absence of
or normalization of blood involvement (B0). Alternately, an absolute
Se´zary cell count is an optional method when good quality smears are
interpreted by a single qualified reader with lower than 250/L24 and
higher than 1,000/L of Se´zary cells1 being reasonable determinants of
B0 and B2.
A future method of tracking blood involvement in MF/SS may
include either measuring the altered expression levels of T-cell anti-
gens or the expression level of genes (mRNA) that are preferentially
expressed by neoplastic T cells compared to normal cells, or the per-
centage of the malignant T-cell clone.37
The recommendation for definition of response in blood is given
in Table 9.
GLOBAL RESPONSE SCORE: DEFINITION
In clinical trials of MF/SS, there has been no uniformity in the defini-
tion of global response (GR), an important assessment affecting over-
all prognosis.19,38 We present in Table 10 the details of a consensus GR
score for MF/SS. Each component of the TNMB staging (ie, skin,
nodes, viscera, and blood) has been given its own definition of re-
sponse (Tables 6 to 9) and these definitions are incorporated in and
used to define the GR score. One important qualifier to the GR score in
MF/SS should be noted: due to the primacy of the response in the skin
in MF/SS, no patient with a global OR should have less than a PR in
the skin.
DEFINITION OF END POINTS
A prolonged OR and progression-free survival are meaningful
primary end points for all patients with MF and SS. However, the
percentage of patients who achieve this OR (response rate), the
time to response, the duration of response, and how it affects the
patient’s prognosis put the significance of the response assessment
in perspective. There has previously been no uniformity in the
definition of CR, PR, stable disease, or PD for MF/SS or in the
Table 9. Response in Blood
Response Definition
CR† B0
PR‡  50% decrease in quantitative
measurements of blood tumor burden
from baseline in those with high tumor
burden at baseline (B2)
SD Fails to attain criteria for CR, PR, or PD
PD§ B0 to B2 or
 50% increase from baseline and at least
5,000 neoplastic cells/L36 or
Loss of response: in those with PR who
were originally B2 at baseline,  50%
increase from nadir and at least 5,000
neoplastic cells/L
Relapse Increase of neoplastic blood lymphocytes to
 B1 in those with CR
Abbreviations: CR, complete response; PR, partial response; SD, stable
disease; PD, progressive disease.
As determined by absolute numbers of neoplastic cells/L.
†If a bone marrow biopsy was performed at baseline and determined to
unequivocally be indicative of lymphomatous involvement, then to confirm a
global CR where blood assessment now meets criteria for B0, a repeat bone
marrow biopsy must show no residual disease or the response should be
considered a PR only.
‡There is no PR in those with B1 disease at baseline as the difference within
the range of neoplastic cells that define B1 is not considered significant and
should not affect determination of global objective response.
§Whichever occurs first.
Table 10. Global Response Score
Global Score Definition Skin Nodes Blood Viscera
CR Complete disappearance of all clinical evidence of disease CR All categories have CR/NI
PR Regression of measurable disease CR All categories do not have a CR/NI and no
category has a PD
PR No category has a PD and if any category
involved at baseline, at least one has a CR or
PR
SD Failure to attain CR, PR, or PD representative of all disease PR No category has a PD and if any category
involved at baseline, no CR or PR in any
SD CR/NI, PR, SD in any category and no category
has a PD
PD Progressive disease PD in any category
Relapse Recurrence disease in prior CR Relapse in any category
Abbreviations: CR, complete response; NI, noninvolved; PR, partial response; PD, progressive disease; SD, stable disease.
It is recommended that not only the proportion of patients who achieve a response or an unfavorable outcome be calculated but a life table account for the length
of the interval during which each patient is under observation also be generated.
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important time points that define duration of response, time to re-
lapse, and other end points. The net result has been, in some instances,
overestimation of the duration of response and in many cases, inability
to directly compare study results. Table 11 details the consensus rec-
ommendations for the definition of end points in clinical trials of
MF/SS, end points which attempt to be in accord with the revised
response criteria for malignant lymphoma19 after taking into account
the unique differences of MF/SS from other NHLs.
SUBJECTIVE OR QUALITY OF LIFE ASSESSMENT
Patients with MF/SS often suffer tremendously from symptoms
related to their disease (eg, pain, pruritus, fatigue, sleep distur-
bance), the social stigmata of having obvious unsightly skin lesions,
the psychological/emotional problems of living with a chronic and
potentially lethal disease, and often financial hardshipsrelated to
therapy. Therefore, it is important that quality of life assessments
Table 11. End Points for Clinical Trials of MF/SS
End Point Patients Definition Comments
ORR CR and PR only Proportion of patients with CR and PR All changes in tumor measurements should be confirmed by
repeat assessment no less than 4 weeks after criteria for
response is first met; in NRCT, OR signifies a degree of
biologic tumor activity of the investigational agent, the
clinical significance which may be suggested by its
magnitude, duration and CR rate; the potential for
documentation of palliative effect in NRCTs increases if a
historical control of patients with similar relevant
prognostic variables is utilized; if feasible, confirmation of
clinical benefit is always best done through a RCT
Time to response CR and PR only Date of initiation of treatment to date when
criteria for response (PR or CR) first met
See above
Response duration CR and PR only Date when criteria for response (CR or PR) first
met until date response first lost; date of loss
of response  date when first meets criteria
for PD or relapse (Tables 5-8)
Responders should have assessments at regular intervals,
generally monthly, to avoid undocumented and potentially
incorrect recording of persistence of response
TTR, also FFR and/or
duration of
complete
response
CR only Date when criteria for CR first met until time of
loss of CR (relapse/recurrence) or death (as a
result of MF/SS or acute toxicity of treatment)
Although a patient with a CR who no longer maintains
complete clearing would no longer be disease free, he/
she would remain a responder until date PR criteria is first
lost
DFS CR only Date when criteria for CR first met until time of
relapse/recurrence or death from any cause
DFS is useful in the setting of adjuvant therapy utilized after
a definitive treatment leading to CR where survival is
predicted to be prolonged; 3- and 5-year DFS are of
particular relevance
Duration stable
disease
All patients Date of initiation of treatment to first date meets
criteria for PD
TTP All patients Date of initiation of treatment to first date meets
criteria for PD or death as a result of MF/SS
In TTP, death from causes other than MF/SS are censored
either at the time of death or at an earlier assessment
and represent a random pattern of loss from the study
PFS All patients Date of initiation of treatment to first date meets
criteria for PD or death as a result of any
cause
PFS is particularly useful as a primary end point in MF/SS
TTF and FFTF All patients Date of initiation of treatment until abandonment
of therapy or the addition of another MF/SS
specific therapy
Abandonment of therapy in TTF/FFTF does not apply to the
conclusion of a standard regimen of a given therapy or
discontinuation of therapy in cases of CR; causes of
abandonment of therapy may include inadequate
response to therapy, intolerable side effects or toxicity,
disease progression, and patient withdrawal for whatever
reason; TTF is particularly difficult to use in reporting
retrospective results of treatments utilized to treat MF/SS
in a clinical practice setting as it is common practice to
add various skin-directed therapies to systemic agents to
augment response
Overall survival All patients Date of initiation of therapy to date of death
from any cause
Evaluation of survival is not optimal in clinical trials of
patients with MF/SS except in those cases with late
stage disease who have failed standard therapies and
have a low performance score and in whom the
duration of the planned trial is long enough to assess
the predicted survival; in the vast majority of MF/SS
patients in clinical trials, expected survival is far longer
than the course of the study and the potential exists
for survival to be impacted by treatment(s) given after
study trial conclusion
Abbreviations: ORR, objective response rate; CR, complete response; PR, partial response; NRCT, nonrandomized clinical trials; RCT, randomized clinical
trials; TTR, time to relapse; FFR, freedom from relapse; TTF, time to treatment failure; FFTF, freedom from treatment failure; DFS, disease-free survival; MF,
mycosis fungoides; SS, Sézary syndrome; RFS, relapse-free survival; PD, progressive disease.
Where death defines the end of DFS, investigators should specify whether secondary to original lymphoma, other cancer, adverse event related to therapy, or
other cause.
Clinical End Points and Response Criteria in Mycosis Fungoides and Se´zary Syndrome
www.jco.org © 2011 by American Society of Clinical Oncology 2605
150.217.1.25
Information downloaded from jco.ascopubs.org and provided by at UNIVERSITA DE FIRENZE on October 25, 2012 from
Copyright © 2011 American Society of Clinical Oncology. All rights reserved.
be included in trials of MF/SS. Both the skin disease-specific
Skindex-29 and the Functional Assessment of Cancer Therapy in
General (FACT-G), measure patient well being. Despite neither
having any specificity for MF/SS, both have been shown to be valid,
reproducible, and sensitive to change, and can be completed in 5
and 10 minutes, respectively.39 The presence of pruritus may be
captured by the Skindex-2940or the Skindex-1641 and quantifica-
tion of severity by a visual analog scale.10 However, to adequately
assess improvement in pruritus as related to a specific treatment,
one needs to determine what constitutes significant pruritus at
baseline, what degree of improvement is necessary to determine
whether the change is significant, and elimination of other factors
that independently could affect pruritus. General terms such as
pruritus relief, which imply, but do not necessarily mean, obliter-
ation of pruritus should be avoided. All comparative pruritus
measurements should be done when other treatments that can
affect pruritus, such as antihistamines, are either at a stable dose or
have been discontinued. No claim of absence or resolution of
pruritus should be made if the measurement is taken while the
patient remains on antipruritic agents. In addition, any change in
pruritus should be correlated to efficacy of the study treatment so that the
result can be put into perspective.
CONCLUSION
These consensus recommendations for standardization of definition
of response in skin, nodes, blood and viscera, GR score, and end points
in MF/SS should now allow for collation of data from different clinical
trials. Given the importance of skin response in MF/SS, both skin and
global response should be reported in clinical trials. This ensures that
the response in the skin, which independently affects prognosis and
quality of life, is not lost within the global score. It is the hope that this
standardization will hasten the communication and collaboration
necessary to find new effective treatments for MF and SS.
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